Advances in management of Thalassemia
- 221 Downloads
Thalassemias represent the most common single-gene disorder causing a major public health problem in India. Thalassemia and hemoglobinopathies probably developed over 7000 years ago as a defense against malaria. In simple terms, thalassemia is caused by a mutation in either the â-globin chain or the á-globin chain which combine equally in red cells to form hemoglobin. These mutations lead to varying degree of anemia resulting into thalassemia minor, intermedia or major. Present write up relates to advances in the management of â-thalassemia major.
Key wordsThalassemias Hemoglobinopathies Anemia Single-gene disorder Management
Unable to display preview. Download preview PDF.
- 2.De SV. Growth and puberty and its management in thalassaemia. Horm Res 2002;58Suppl 1:72–79.Google Scholar
- 6.Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta thalassaemia major: Application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003;121:938–948.PubMedCrossRefGoogle Scholar
- 8.Jensen PD, Jansen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with desferrioxamine indication of close relation between myocardial iron content and chelation iron pool. Blood 2003; 101:4632–4639.PubMedCrossRefGoogle Scholar
- 10.Agarwal MB. ICL 670: A new oral chelator: A major breakthrough in treatment of thalassaemia. Ind J Hematol & Bl Trans 2003; 31: 26–28.Google Scholar
- 14.Erer B, Lucarelli G. Bone marrow transplantation in thalassaemia. Turk J Hematol 1999;16:147–159.Google Scholar